Here we have reviewed current pharmacological methods of targeting SAM production via MAT2A inhibition and direct PRMT5 inhibition (both of which reduce PRMT5-specific methylation reactions) and reported evidence for and against the selectivity of these treatments for MTAP-negative tumours. Here, MAT2A is linked to neoplasm.